All In Biotech

Free tool

FAERS Monitor: Ic-Green

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 011525 or its brand name (Ic-Green, Indocyanine Green). Reports on generic versions are filed under their own applications.

Reports

121

Serious

105

87% of reports

Hospitalization

25

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • palpitations10
  • urticaria10
  • off label use9
  • visual acuity reduced9
  • drug ineffective8
  • dyspnoea8
  • haemangioma congenital8
  • low birth weight baby8
  • patent ductus arteriosus8
  • rash8
  • disease progression7
  • hypotension7
  • liver function test increased7
  • abdominal pain6
  • dizziness6

Reports by year received

View as table
YearReports
20081
20093
20102
20112
20126
20145
20152
20168
20178
201817
20197
20205
20213
202213
202311
20246
202511
202611

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,038 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemangioma congenitalSignal82974.41513.320,548
patent ductus arteriosusSignal8351.0179.52,448
low birth weight babySignal8175.289.61,216
liver function test increasedSignal756.727.6330
visual acuity reducedSignal947.125.1362
palpitationsSignal1014.88.2116
urticariaSignal1010.45.776
disease progressionSignal710.35.050
hypotensionSignal76.13.025
abdominal painSignal64.52.113
rashSignal83.21.610
dyspnoeaSignal82.51.36
dizziness62.11.02
off label use91.81.02
drug ineffective81.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.